ArticleLeukemia2026

Aberrant expression of MERTK activates BCR via CD79a in CLL cells: alternative therapeutic strategy for relapsed/refractory CLL.

Mariana T Mendez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.